Linda Burghardt, PhD, a researcher in Great Neck, New York, started taking semaglutide because her doctor thought it might ...

CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but ...

The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access ...

Some Medicare enrollees may soon be able to access super-popular drugs for obesity under a voluntary model program, the ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

The new year could bring dramatic changes to health care. Michigan doctors highlight the top 5 things they expect to see in ...

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering doses of 1.5 ...

As Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more accessible to millions. With ...

Gestational diabetes rose from 58.2 to 79.3 per 1,000 live births from 2016 to 2024, with highest rates among American Indian ...

The lowest doses of the daily pill will cost $149 a month for people paying out of pocket, offering a cheaper alternative to ...